GlobeNewswire: Peregrine Pharmaceuticals Inc. Contains the last 10 of 87 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T11:22:36ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/01/05/1284178/0/en/Peregrine-Pharmaceuticals-Announces-Name-Change-to-Avid-Bioservices-as-Part-of-Transition-to-Dedicated-Contract-Development-and-Manufacturing-Organization-CDMO.html?f=22&fvtc=4&fvtv=25131Peregrine Pharmaceuticals Announces Name Change to Avid Bioservices as Part of Transition to Dedicated Contract Development and Manufacturing Organization (CDMO) 2018-01-05T13:05:00Z<![CDATA[Company Adopts “CDMO” as New Nasdaq Ticker Symbol; Will Initiate Trading Under New Ticker on January 8, 2018 Company Adopts “CDMO” as New Nasdaq Ticker Symbol; Will Initiate Trading Under New Ticker on January 8, 2018 ]]>https://www.globenewswire.com/news-release/2018/01/02/1277032/0/en/Peregrine-Pharmaceuticals-to-Present-at-Biotech-Showcase-2018.html?f=22&fvtc=4&fvtv=25131Peregrine Pharmaceuticals to Present at Biotech Showcase 20182018-01-02T13:05:00Z<![CDATA[TUSTIN, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing and delivering high quality biologics, today announced that its president and chief executive officer, Roger J. Lias, Ph.D., will deliver a corporate presentation at the 10th Annual Biotech Showcase™, being held January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco.]]>https://www.globenewswire.com/news-release/2017/12/26/1274589/0/en/Peregrine-Pharmaceuticals-Announces-Appointment-of-Roger-J-Lias-Ph-D-as-President-and-Chief-Executive-Officer.html?f=22&fvtc=4&fvtv=25131Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D., as President and Chief Executive Officer2017-12-26T13:05:00Z<![CDATA[TUSTIN, Calif., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing and delivering high quality biologics, today announced the appointment of Roger J. Lias, Ph.D., as the company’s new president and chief executive officer. Dr. Lias, who has more than 20 years of contract development and manufacturing organization (CDMO) management experience, currently sits on the Peregrine board of directors and serves as president of Avid Bioservices, Peregrine’s wholly-owned CDMO subsidiary. Dr. Lias succeeds Steven W. King, who resigned as president and chief executive officer of Peregrine to pursue other professional interests.]]>https://www.globenewswire.com/news-release/2017/12/11/1251063/0/en/Peregrine-Pharmaceuticals-Reports-Financial-Results-for-Second-Quarter-of-Fiscal-Year-2018-and-Recent-Developments.html?f=22&fvtc=4&fvtv=25131Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments2017-12-11T21:05:00Z<![CDATA[-- Avid Bioservices Records Revenues of $12.8 Million in the Second Quarter of FY2018 -- -- Transition to a Dedicated CDMO Business Nearing Completion --TUSTIN, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing and delivering high quality biologics, today announced financial results for the second quarter of fiscal year (FY) 2018 ended October 31, 2017, and provided an update on its contract manufacturing operations, and other corporate highlights.]]>https://www.globenewswire.com/news-release/2017/12/07/1247747/0/en/Peregrine-Pharmaceuticals-Declares-Quarterly-Dividend-on-its-Series-E-Convertible-Preferred-Stock.html?f=22&fvtc=4&fvtv=25131Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock2017-12-07T21:05:00Z<![CDATA[TUSTIN, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").]]>https://www.globenewswire.com/news-release/2017/12/04/1220274/0/en/Peregrine-Pharmaceuticals-to-Report-Financial-Results-for-Second-Quarter-of-Fiscal-Year-2018-After-Market-Close-on-December-11-2017.html?f=22&fvtc=4&fvtv=25131Peregrine Pharmaceuticals to Report Financial Results for Second Quarter of Fiscal Year 2018 After Market Close on December 11, 20172017-12-04T21:05:00Z<![CDATA[TUSTIN, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company focused on helping improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2018 ended October 31, 2017 on December 11, 2017 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the second quarter and review recent corporate developments.]]>https://www.globenewswire.com/news-release/2017/11/28/1206879/0/en/Peregrine-Pharmaceuticals-Ronin-Trading-and-SW-Investment-Management-Announce-Settlement-Agreement.html?f=22&fvtc=4&fvtv=25131Peregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement Agreement2017-11-28T13:05:00Z<![CDATA[Peregrine Board Reconstituted with Four New Independent Directors Peregrine Board Reconstituted with Four New Independent Directors]]>https://www.globenewswire.com/news-release/2017/11/13/1185130/0/en/Peregrine-Announces-Date-of-2017-Annual-Meeting-of-Stockholders.html?f=22&fvtc=4&fvtv=25131Peregrine Announces Date of 2017 Annual Meeting of Stockholders2017-11-13T13:05:00Z<![CDATA[TUSTIN, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP) today announced that its 2017 Annual Meeting of Stockholders will be held on January 18, 2018, at 14191 Myford Road, Tustin, California 92780, located within the company’s manufacturing campus. Holders of the company’s common stock at the close of business on November 27, 2017, the record date, will be entitled to receive notice of and vote their shares at the 2017 Annual Meeting.]]>https://www.globenewswire.com/news-release/2017/10/24/1152327/0/en/Peregrine-Pharmaceuticals-Announces-Appointment-of-Patrick-Walsh-to-Board-of-Directors-of-Peregrine-and-Avid-Bioservices.html?f=22&fvtc=4&fvtv=25131Peregrine Pharmaceuticals Announces Appointment of Patrick Walsh to Board of Directors of Peregrine and Avid Bioservices2017-10-24T12:05:00Z<![CDATA[Industry Veteran with More Than Thirty Years of Experience Leading Successful Contract Development and Pharmaceutical Manufacturing Organizations Industry Veteran with More Than Thirty Years of Experience Leading Successful Contract Development and Pharmaceutical Manufacturing Organizations]]>https://www.globenewswire.com/news-release/2017/10/19/1150386/0/en/Peregrine-Pharmaceuticals-Announces-Appointment-of-Mark-R-Bamforth-to-Board-of-Directors-of-Peregrine-and-Avid-Bioservices.html?f=22&fvtc=4&fvtv=25131Peregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid Bioservices2017-10-19T12:05:00Z<![CDATA[Senior Executive with Thirty Years of Biologics Experience including Contract Development and Manufacturing Organization (CDMO) Leadership Senior Executive with Thirty Years of Biologics Experience including Contract Development and Manufacturing Organization (CDMO) Leadership]]>